bioRxivImmunology
Concurrent administration of COVID-19 and influenza vaccines enhances Spike-specific antibody responses
S. E. Barouch, T. M. Chicz, R. Blanc, D. R. Barbati, L. J. Parker, X. Tong, R. P. McNamara
Abstract
The bivalent COVID-19 mRNA boosters became available in fall 2022 and were recommended alongside the seasonal influenza vaccine. However, the immunogenicity of concurrent versus separate administration of these vaccines remains unclear. Here, we analyzed antibody responses in healthcare workers who received the bivalent COVID-19 booster and the influenza vaccine on the same day or different days. IgG1 responses to SARS-CoV-2 Spike were higher at peak immunogenicity and 6 months following concurrent administration compared with separate administration of the COVID-19 and influenza vaccines. These data suggest that concurrent administration of these vaccines may yield higher and more durable SARS-CoV-2 antibody responses.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development and Characterization of Recombinant Vesicular Stomatitis Virus (rVSV)-based Bivalent Vaccine Against COVID-19 Delta Variant and Influenza Virus
Z. Ao, M. Jing Ouyang, … X. Yao·bioRxiv·Dec 14, 2021
- A 10-valent composite mRNA vaccine against both influenza and COVID-19
- Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccine
R. R. Chaparian, A. T. Harding, … B. E. Heaton·bioRxiv·Apr 30, 2021
- Monovalent XBB.1.5 mRNA Vaccine Recalls a More Durable and Coordinated Antibody Response to SARS-CoV-2 Spike than the Bivalent WT/BA.5 mRNA Vaccine
Susanna E Barouch, Kate S Levine, … Ryan P. McNamara·bioRxiv·Sep 12, 2024
- Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination
F. Amanat, J. Clark, … F. Krammer·bioRxiv·Oct 25, 2022
- Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and QuadrivalentSeasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant
M. J. Massare, N. Patel, … G. Smith·bioRxiv·May 5, 2021